Research has uncovered persistent disparities in preventive cancer care across different sexual orientation and gender identity populations. The study, conducted by researchers at The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, found particular concern for cervical and breast cancer screening.
Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
